PET-CT in radiation oncology - The impact on diagnosis, treatment planning, and assessment of treatment response

被引:46
作者
Heron, Dwight E. [1 ]
Andrade, Regiane S. [1 ]
Beriwal, Sushil [1 ]
Smith, Ryan P. [1 ]
机构
[1] Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA 15260 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2008年 / 31卷 / 04期
关键词
positron emission tomography-computed tomography; assessment of response; image-guided radiation therapy; treatment planning;
D O I
10.1097/COC.0b013e318162f150
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To review the role of hybrid positron emission tomography (PET)-computed tomography (CT) systems in the design and management of cancer patients in the modern radiation oncology practice. PET is co-registered with CT and incorporated into a systematic approach to the staging, management, and assessment of response and surveillance of a variety of oncologic diagnoses. Methods: A review of the literature of functional imaging such as PET-C-T in staging, treatment plan design, assessment of response and detection of recurrence for tumors involving the head and neck, lung, esophagus, rectum amongst others. Results: PET and PET-CT offer significant advantages which include more accurate staging which often results in management changes in roughly one-third of patients across a number of disease site. More accurate target definition may augment highly conformal radiation treatment plans using intensity-modulated radiation therapy and stereotactic radiosurgery and radiotherapy. Conclusion: The emerging data appears to suggest the functional imaging may be a more useful tool to evaluate the therapeutic effect of treatment, detect early failures and prognosticate long-term outcome.
引用
收藏
页码:352 / 362
页数:11
相关论文
共 135 条
[1]   Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings [J].
Abdel-Nabi, H ;
Doerr, RJ ;
Lamonica, DM ;
Cronin, VR ;
Galantowicz, P ;
Carbone, GM ;
Spaulding, MB .
RADIOLOGY, 1998, 206 (03) :755-760
[2]   The postoperative surveillance of patients with colon cancer and rectal cancer [J].
Abir, Farshad ;
Alva, Suraj ;
Longo, Walter E. ;
Audiso, Riccardo ;
Virgo, Katherine S. ;
Johnson, Frank E. .
AMERICAN JOURNAL OF SURGERY, 2006, 192 (01) :100-108
[3]   IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk [J].
Ahmed, RS ;
Kim, RY ;
Duan, J ;
Meleth, S ;
De Los Santos, JF ;
Fiveash, JB .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (02) :505-512
[4]   Comparison between 2-deoxy-2-[18F]fluoro-D-Glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma [J].
Allen-Auerbach, M ;
Quon, A ;
Weber, WA ;
Obrzut, S ;
Crawford, T ;
Silverman, DHS ;
Ratib, O ;
Phelps, ME ;
Czernin, J .
MOLECULAR IMAGING AND BIOLOGY, 2004, 6 (06) :411-416
[5]  
Amthauer H, 2006, NUKLEARMED-NUCL MED, V45, P177
[6]  
Andrade R, 2006, RADIOTHER ONCOL, V81, pS488
[7]   Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers [J].
Andrade, Regiane S. ;
Heron, Dwight E. ;
Degirmenci, Berna ;
Filho, Pedro A. A. ;
Branstetter, Barton F. ;
Seethala, Raja R. ;
Ferris, Robert L. ;
Avril, Norbert .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (05) :1315-1322
[8]  
ANDRADE RS, 2006, ARCH OTOLARYNGOL, V132, P879
[9]   The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer [J].
Ashamalla, H ;
Rafla, S ;
Parikh, K ;
Mokhtar, B ;
Goswami, G ;
Kambam, S ;
Abdel-Dayem, H ;
Guirguis, A ;
Ross, P ;
Evola, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (04) :1016-1023
[10]   Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer [J].
Avril, N ;
Sassen, S ;
Schmalfeldt, B ;
Naehrig, J ;
Rutke, S ;
Weber, WA ;
Werner, M ;
Graeff, H ;
Schwaiger, M ;
Kuhn, W .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7445-7453